What is the TRH stimulation test?

The TRH test involves injecting TRH and measuring TSH response. It helps distinguish between different causes of thyroid dysfunction and assess pituitary reserve. It's less commonly used now with highly sensitive TSH assays available.

Can TRH help with depression?

Some research has shown antidepressant-like effects of TRH in studies, but this hasn't translated to clinical use, partly due to its very short half-life and the complexity of central administration.

Why is TRH a tripeptide but still called a hormone?

Despite its small size, TRH meets the definition of a hormone: a chemical messenger produced in one tissue (hypothalamus) that travels through blood to affect another tissue (pituitary). Size doesn't determine hormone status.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Hormonal & Endocrine•Updated 2026-02-01•5 min read

What Is TRH? Benefits, Research & Safety

A hypothalamic tripeptide that regulates thyroid function and has diverse effects on the brain and metabolism.

Share:X Post LinkedIn

Also known as:

Thyrotropin-Releasing Hormone

Protirelin

TRF

AStrong human evidenceUK: Prescription-only (UK POM)WADA: Sport status unclear

UK summary: Endogenous hypothalamic hormone. Synthetic TRH (protirelin) is used clinically for thyroid-axis testing; not appropriate for wellness self-administration.

Quick Facts

Overview

Thyrotropin-releasing hormone (TRH) is a tripeptide (pGlu-His-Pro-NH2) produced in the hypothalamus that stimulates the release of thyroid-stimulating hormone (TSH) from the anterior pituitary. It was the first hypothalamic releasing hormone to be characterised, a discovery that earned Roger Guillemin and Andrew Schally the Nobel Prize. Beyond its classical role in thyroid regulation, TRH has numerous effects throughout the body including modulation of the nervous system, gastrointestinal function, and potentially the immune system. TRH and its receptors are distributed in many tissues beyond the hypothalamic-pituitary axis. TRH (protirelin) has clinical utility in diagnostic testing of pituitary and thyroid function. It has also been researched for neurological conditions, depression, and other disorders, though therapeutic applications remain limited. The very short half-life of TRH (minutes) has driven research into TRH analogues with improved stability for therapeutic applications. Some analogues have shown promise in neurological conditions. Understanding TRH biology continues to be important for thyroid physiology and the broader understanding of hypothalamic control of endocrine function.

Evidence standards summary

TRH — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

AStrong human evidenceOverall grade against our evidence grading methodology.

Endogenous hypothalamic hormone. Synthetic TRH (protirelin) is used clinically for thyroid-axis testing; not appropriate for wellness self-administration.

02Human evidence grade

AStrong human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Protirelin available for diagnostic use.
EU: Available for diagnostic purposes in some countries.
Notes: TRH (protirelin) is approved for diagnostic testing of pituitary-thyroid axis function. Therapeutic applications are limited. Some TRH analogues are approved in Japan for neurological conditions.

05Approved medical uses

TRH (protirelin) for thyroid-axis stimulation testing — hospital use.

06Unapproved / promotional claims

TRH treats hypothyroidism.
TRH boosts metabolism for fat loss.

07Common internet claims

Marketed by some research-peptide vendors for thyroid 'support' or 'metabolic boost'.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“TRH treats hypothyroidism”	E	No	High	Hypothyroidism is treated with thyroid hormones (levothyroxine etc), not with TRH. TRH is for diagnostic testing.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Transient flushing, urgency, hypertension during diagnostic test.
Not appropriate for self-administration; underlying thyroid dysfunction needs investigation.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Prescription-only (UK POM)

Protirelin available for diagnostic use.

14EU legal position

Available for diagnostic purposes in some countries.

15What this page cannot tell you

Whether self-administered TRH improves any clinical outcome.
Whether grey-market TRH products contain the labelled compound.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Therapeutic use of TRH was largely superseded by direct thyroid hormone replacement.

19Safer alternatives / established care pathways

NHS GP / endocrinology workup for suspected hypothyroidism — TSH, free T4, antibodies.
Licensed levothyroxine for confirmed hypothyroidism.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

What thyroid investigations and licensed treatments are appropriate for my symptoms?

Discovery & History

The search for hypothalamic releasing factors began in the 1950s, based on evidence that the hypothalamus controlled pituitary function through chemical messengers. Roger Guillemin and Andrew Schally led competing research programs. TRH was the first releasing hormone to be identified and characterised. In 1969-1970, both Guillemin's and Schally's groups independently determined its structure as a simple tripeptide (pyroglutamyl-histidyl-prolineamide). The simplicity of TRH's structure was surprising—a tripeptide controlling a major hormone axis. Its characterisation opened the door to identifying other releasing hormones (GnRH, GHRH, CRH, somatostatin) and established neuroendocrinology as a field. Guillemin and Schally shared the Nobel Prize in Physiology or Medicine in 1977 for their discoveries concerning "the peptide hormone production of the brain." Clinical applications developed for TRH as a diagnostic agent (TRH stimulation test) for pituitary-thyroid disorders. Research also explored therapeutic uses in depression and neurological conditions, though with limited translation to practice. TRH analogues with improved stability have been developed and studied for conditions including amyotrophic lateral sclerosis (ALS) and spinocerebellar degeneration, with some approved in Japan for these indications.

Mechanism of Action

TRH acts through specific G protein-coupled receptors with effects in multiple systems: **TRH Receptor Activation** Two TRH receptors have been identified (TRH-R1 and TRH-R2): - Couple to Gq proteins - Activate phospholipase C - Increase intracellular calcium - Expressed in pituitary and widely in brain **Pituitary Effects (Classical)** The primary endocrine function: - Stimulates TSH release from thyrotrophs - Also releases prolactin from lactotrophs - Rapid and potent effect - Subject to thyroid hormone feedback **Central Nervous System Effects** TRH has numerous CNS actions: - Neuromodulatory and neurotransmitter effects - Arousal and behavioural activation - Antidepressant-like effects in some models - Possible neuroprotective properties - Effects on temperature regulation **Gastrointestinal Effects** TRH affects gut function: - Stimulates gastric acid secretion - Affects gastrointestinal motility - Present in enteric nervous system **Metabolic Effects** Effects on metabolism beyond thyroid: - Direct effects on food intake (complex) - Thermogenic properties - Interactions with energy homeostasis

Researched Benefits

Based on preclinical and clinical research findings:

1
Diagnostic utility in pituitary-thyroid assessment
2
Potential antidepressant effects (research)
3
Possible neuroprotective properties
4
Arousal and alertness enhancement
5
Thermogenic effects
6
TRH analogues approved for some neurological conditions (Japan)

Claim vs Evidence

How popular claims about TRH stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“TRH treats hypothyroidism”	E	No	High	Hypothyroidism is treated with thyroid hormones (levothyroxine etc), not with TRH. TRH is for diagnostic testing.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	200-500 mcg IV for diagnostic TRH stimulation test
Frequency	Single dose for diagnostic test
Duration	Acute diagnostic procedure
Notes	TRH (protirelin) is used clinically for diagnostic testing. Therapeutic applications are limited by very short half-life. TRH analogues have been developed with improved stability for potential neurological applications.

Administration Routes

Routes studied in research settings (educational only):

Intravenous (diagnostic testing)
Some oral TRH analogues studied

Half-Life	Stability
Approximately 5 minutes (very short)	Rapidly degraded by serum enzymes; requires IV administration for diagnostic use

Safety Profile & Known Risks

Commonly Reported Side Effects

Nausea
Flushing
Urge to urinate
Light-headedness
Transient blood pressure changes
Strange taste in mouth

Rare Risks & Concerns

Blood pressure spikes in susceptible individuals
Rare bronchospasm
Pituitary apoplexy in patients with pituitary tumours (rare)

Contraindications

Known hypersensitivity
Uncontrolled hypertension
Recent myocardial infarction
Asthma (relative)

UK & EU Regulatory Context

🇬🇧 United Kingdom

Protirelin available for diagnostic use.

🇪🇺 European Union

Available for diagnostic purposes in some countries.

TRH (protirelin) is approved for diagnostic testing of pituitary-thyroid axis function. Therapeutic applications are limited. Some TRH analogues are approved in Japan for neurological conditions.

Clinical Studies Summary

Drug treatment for spinal muscular atrophy types II and III.

Nusinersen improves motor function in SMA type II, based on moderate-certainty evidence. Creatine, gabapentin, hydroxyurea, phenylbutyrate, valproic acid and the combination of valproic acid and ALC probably have no clinically important effect on motor function in SMA types II or III (or both) based on low-certainty evidence, and olesoxime and somatropin may also have little to no clinically important effect but evid…

Cochrane Database Syst Rev. 2020View on PubMed

Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease.

Prenatal TRH in addition to corticosteroids, given to women at risk of preterm birth, does not improve infant outcomes and can cause maternal side effects. Therefore, all tasks relating to these studies (assessment of eligibility for inclusion, assessment of risk of bias, and data extraction) were carried out by other members of the review team who were not directly involved in the trials.

Cochrane Database Syst Rev. 2013View on PubMed

Targeting the brain-gut-prostate axis in chronic prostatitis: mechanisms and therapeutics.

, Th17/Treg imbalance) are explored, alongside innovative therapies such as microbiome modulation, neural interventions, and immune regulation. This holistic paradigm not only provides new mechanistic insights but also offers promising avenues for personalized management and translational research in CP/CPPS, potentially overcoming current therapeutic bottlenecks.

Front Endocrinol (Lausanne). 2025View on PubMed

Early tumor-related hemorrhage after stereotactic radiosurgery of brain metastases: Systematic review of reported cases.

Early TRH is very rare, but potentially life-threatening complication of SRS for BM; thus, its risk (while extremely low) and possible consequences should be discussed at the time of obtaining informed consent.

J Clin Neurosci. 2023View on PubMed

Hypothalamic-pituitary-thyroid (HPT) axis functioning in anxiety disorders. A systematic review.

The findings resonate well with clinical recommendations to routinely screen for thyroid disorders in patients with anxiety disorders, and with what is known from basic research about thyroid-brain interactions. The results of the risk of bias assessment underscore the importance of further high-quality experimental and longitudinal epidemiological research.

Depress Anxiety. 2018View on PubMed

Thyroid adverse effects of psychotropic drugs: a review.

Patients receiving lithium, phenothiazines, and tricyclic antidepressants TCA should be closely monitored for the development of thyroid function abnormalities. Only patients at risk for developing thyroid function abnormalities should be monitored when they receive typical and/or atypical antipsychotic drugs, nontricyclic antidepressant drugs, and carbamazepine.

Clin Neuropharmacol. 2011View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

17 of 21 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding

N/A

Status: Not Yet Recruiting · 120 participants · Bahcesehir Cyprus University

Conditions: Mitochondrial Degradation, Autophagy, Fasting

No results postedNCT07638696

The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)

PHASE2

Status: Not Yet Recruiting · 26 participants · Universiti Kebangsaan Malaysia Medical Centre

Conditions: Alcoholic Fatty Liver Disease

No results postedNCT07466485

Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases

PHASE2

Status: Not Yet Recruiting · 30 participants · Affiliated Hospital of Nantong University

Conditions: Diabetic Keratopathy

No results postedNCT07382453

Shoulder Denervation for Post Mastectomy Irradiation Shoulder Pain

Status: Recruiting · 60 participants · National Cancer Institute, Egypt

Conditions: Breast Cancer

No results postedNCT07095569

LIRRH Trial for the Right-sided Colon Cancer

Status: Recruiting · 120 participants · Chaoxi Zhou

Conditions: Ascending Colon Cancer, Proximal Transverse Colon Cancer

No results postedNCT07207317

Comparison of Pulsed and Thermal Radiofrequency for Trigeminal Neuralgia

Status: Recruiting · 60 participants · Zagazig University

Conditions: Trigeminal Neuralgia

No results postedNCT06684275

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

Status: Recruiting · 300 participants · Centre Hospitalier Universitaire de Liege

Conditions: Neuromuscular Diseases, Obesity (Disorder), Myotonic Dystrophy 1

No results postedNCT07136844

The Alkmaar MLPTI Cohort Study: Outcomes at 9 Years

Status: Active Not Recruiting · 153 participants · Noordwest Ziekenhuisgroep

Conditions: Preterm Birth, Developmental Delay, Growth Delay

No results postedNCT05990582

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

Status: Recruiting · 568 participants · Zhejiang University

Conditions: Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer

No results postedNCT05923255

Time Restricted Eating for the Treatment of Type 2 Diabetes

Status: Completed · 75 participants · University of Illinois at Chicago

Conditions: Diabetes Mellitus, Type 2, Obesity

No results postedNCT05225337

Effects of TRF on Obese Patients With CKD Stage 3-4

Status: Completed · 28 participants · Guangdong Provincial Hospital of Traditional Chinese Medicine

Conditions: Time Restricted Feeding, Renal Insufficiency, Chronic, Obesity

No results postedNCT05037747

Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer

PHASE1

Status: Withdrawn · Memorial Sloan Kettering Cancer Center

Conditions: Thyroid Cancer

No results postedNCT04868045

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for TRH?

Source research-grade TRH from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about TRH

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

What thyroid investigations and licensed treatments are appropriate for my symptoms?

UK regulatory & safety context

Prescription-only medicines

Safety Centre guide

Related Peptides

GnRH

The master hypothalamic hormone controlling reproductive function, with both agonist and antagonist analogues used therapeutically.

Learn more

Explore More Peptides

Browse our comprehensive database of research-backed peptide profiles.